Further results showed that the inhibitory effect of sortilin knockdown on GBM invasion and mesenchymal transition could be reversed by aGSK-3β inhibitor, indicating that GSK-3β/β-catenin is critical for sortilin-induced GBM invasion and mesenchymal transition. The gene discussed is SORT1; the disease is glioblastoma.